Fluoxetine (Reconcile) for Canine Behavior Disorders

Bottom line

Fluoxetine is the first-line SSRI for canine anxiety, compulsive, and fear-based disorders, and it is the only fluoxetine product FDA-approved for dogs: Reconcile (chewable fluoxetine hydrochloride) is labeled for canine separation anxiety in conjunction with a behavior-modification plan [1]. Dose it at 1–2 mg/kg PO q24h and counsel owners that behavioral benefit typically emerges within 2–4 weeks, with full reassessment by 8 weeks [3] — it is not a situational anxiolytic [1]. It is contraindicated with MAOIs (selegiline/L-deprenyl and the amitraz tick collar) and in dogs with epilepsy or a seizure history, and it carries serotonin-syndrome risk when stacked with other serotonergics [1]. Never use it as monotherapy; efficacy in the pivotal trial required a concurrent behavior plan [1][2].

Drug facts

Fluoxetine is a selective serotonin reuptake inhibitor (SSRI). It inhibits presynaptic serotonin reuptake at the synaptic cleft, raising available 5-HT; the clinically meaningful effect emerges over weeks rather than from the acute reuptake block, which is why benefit is delayed.

• MOA: "Fluoxetine exerts its effect by inhibiting the reuptake of serotonin at the pre-synaptic neuron. Fluoxetine does not act as a sedative" [1].
• Metabolism: ~72% oral absorption, then hepatic cytochrome P-450 metabolism to norfluoxetine, an equipotent SSRI that contributes to efficacy. Parent fluoxetine T½ ≈ 6.2 h, but norfluoxetine T½ ≈ 49 h drives the long functional half-life and the extended washout [1].
• Approval status: Reconcile is FDA-approved for canine separation anxiety [1]. Generic fluoxetine is used off-label for aggression, compulsive/stereotypic disorders, other anxiety disorders, and urine marking [4][5].
• Formulations: Reconcile beef-flavored chewable tablets in 8, 16, 32, and 64 mg strengths; generic human fluoxetine (capsules/tablets/oral solution) is used off-label [1].

Indications

On-label: canine separation anxiety, always paired with a behavior-modification plan [1]. The label explicitly notes Reconcile is not recommended for the treatment of aggression and has not been clinically tested for other behavioral disorders [1].

Off-label (generic fluoxetine), supported by peer-reviewed evidence:

• Compulsive/stereotypic disorders — a randomized, controlled trial (63 dogs, 1–2 mg/kg PO q24h) found fluoxetine superior to placebo by week 6 for canine compulsive disorder [5].
• Owner-directed and other aggression — used off-label alongside behavior therapy, despite the Reconcile label's aggression caveat [4]. Set owner expectations carefully and pair with a safety plan.
• Generalized anxiety, noise/fear-based disorders, and urine marking — SSRIs including fluoxetine are used for these presentations in behavioral pharmacology references [4].

Flag off-label use to the owner and document informed consent.

Dosing

1–2 mg/kg PO q24h (0.5–0.9 mg/lb), given with or without food; this is both the Reconcile label dose and the dose used in the separation-anxiety and compulsive-disorder RCTs [1][2][5].

• Titration: many clinicians start at the low end (or ~0.5 mg/kg) for 1–2 weeks to limit early anorexia/sedation, then move to the target dose. If an adverse reaction emerges, a dose reduction resolved or reduced signs in the label field studies, and roughly half of dogs tolerated a return to full dose after 1–2 weeks [1].
• Ceiling: doses above 2 mg/kg/day are not label-supported and carry a higher adverse-effect burden with no established added benefit [1].
• Not PRN: because the effect is neuroadaptive, this is a daily maintenance drug, not a situational anxiolytic. For an acute/event-based need (storms, vet visits), layer a fast-acting agent rather than up-titrating fluoxetine.
• Missed dose: give the next scheduled dose as prescribed; do not double up [1].

Onset & what to tell the owner

Tell owners full behavioral benefit takes about 4–6 weeks and to commit to an adequate trial before judging efficacy. Merck's behavioral-pharmacology reference frames SSRI onset as 7–30 days [4]; the Reconcile label directs reassessment at 8 weeks and reevaluation of case management if there is no improvement by then [1].

Counsel them that:

• Early sedation, reduced appetite, or a transient uptick in anxiety/agitation in the first week or two is common and usually settles [1][4].
• The drug works only alongside the behavior plan — pills without behavior modification "may not provide any lasting benefit" per the label [1].
• They should not stop abruptly on their own or expect a "calming pill" effect the same day.

Adverse effects

The most common signal is appetite suppression and sedation, most pronounced early. In the North American field studies (n=216 treated), reported reactions included calm/lethargy/depression 32.9%, decreased appetite 26.9%, vomiting 17.1%, shaking/shivering/tremor 11.1%, diarrhea 9.7%, and restlessness 7.4% [1].

• Weight loss: ≥5% loss from baseline in 29.6% of treated dogs vs 13.0% of controls — weigh at rechecks [1].
• Neurologic: transient agitation, restlessness, disorientation, or incoordination; seizures were reported even in dogs with no seizure history, so fluoxetine may lower seizure threshold [1].
• Paradoxical: rare increased aggression/agitation — reassess promptly if a dog worsens after starting therapy [1].
• Post-approval reports (decreasing frequency): decreased appetite, depression/lethargy, tremor, vomiting, restlessness/anxiety, seizures, aggression, diarrhea, mydriasis, vocalization, weight loss, panting, confusion, incoordination, hypersalivation [1].

Drug interactions & contraindications

Contraindicated in dogs with epilepsy or a history of seizures, and should not be combined with seizure-threshold-lowering drugs (e.g., phenothiazines such as acepromazine or chlorpromazine) [1]. Also contraindicated with known hypersensitivity to fluoxetine or other SSRIs [1].

MAOIs — do not combine. Reconcile "should not be given in combination with a monoamine oxidase inhibitor (MAOI) [e.g., selegiline hydrochloride (L-deprenyl) or amitraz], or within a minimum of 14 days of discontinuing therapy with an MAOI" [1]. Remember amitraz is an MAOI — screen for the amitraz-impregnated tick collar and amitraz dips before starting fluoxetine.

Serotonin syndrome. Stacking fluoxetine with other serotonergic agents — tramadol, trazodone, TCAs (e.g., clomipramine, amitriptyline), other SSRIs, or MAOIs — risks serotonin syndrome (hyperthermia, tremor, agitation, autonomic instability). The label notes TCA co-administration has not been formally studied [1].

Long washout. Because fluoxetine and norfluoxetine have long half-lives, observe a 6-week washout after discontinuing before starting any drug that may adversely interact [1]. Use caution with any agent affecting the CYP450 system (fluoxetine inhibits these enzymes) and in hepatic disease, given hepatic metabolism [1][4].

Monitoring & discontinuation

Reassess at ~4–6 weeks for behavioral response and again by the 8-week mark; if there is no improvement by 8 weeks, reevaluate the diagnosis and case management [1]. At rechecks, track body weight and appetite (the most common tolerability issues) and screen for agitation or any paradoxical worsening [1].

• Baseline physical exam and age-/health-appropriate labs before starting; the label recommends ruling out non-behavioral causes first [1].
• Discontinuation: per the label, because of the long half-life it is not necessary to taper Reconcile, and continued behavior modification is recommended to prevent relapse [1]. In practice, many clinicians still taper after prolonged use, and the drug's own long elimination provides a built-in self-taper.
• Long-term (>8 weeks) effectiveness and safety were not formally evaluated in the pivotal field study, so use professional judgment on continuing therapy and monitor accordingly [1].

Frequently Asked Questions

What is the fluoxetine dose for dogs? 1-2 mg/kg PO once daily. This is the Reconcile label dose and the dose used in the pivotal separation-anxiety and compulsive-disorder trials. Many clinicians start at the low end (or ~0.5 mg/kg) for 1-2 weeks to limit early anorexia and sedation before reaching the target dose. Doses above 2 mg/kg/day are not label-supported and add adverse-effect burden without established benefit.

How long does fluoxetine take to work in dogs? Expect roughly 4-6 weeks for full behavioral benefit; behavioral-pharmacology references cite an SSRI onset window of 7-30 days. It is a daily maintenance drug, not a situational anxiolytic, so counsel owners to commit to an adequate trial. The Reconcile label directs reassessing at 8 weeks and reevaluating case management if there is no improvement by then.

Is fluoxetine FDA-approved for dogs? Yes. Reconcile (chewable fluoxetine hydrochloride) is FDA-approved for canine separation anxiety in conjunction with a behavior-modification plan. Generic fluoxetine is used off-label for aggression, compulsive/stereotypic disorders, other anxiety disorders, and urine marking; flag off-label use and document consent.

Can fluoxetine be combined with trazodone, clomipramine, or tramadol? Do so only with caution and awareness of serotonin-syndrome risk. Fluoxetine plus other serotonergics (trazodone, tramadol, TCAs like clomipramine, other SSRIs) can precipitate serotonin syndrome (hyperthermia, tremor, agitation, autonomic instability). Combining an SSRI with a TCA was not formally studied on the label; if you co-prescribe, monitor closely and educate the owner on warning signs.

Why is fluoxetine contraindicated with amitraz and selegiline? Both are MAOIs, and fluoxetine should not be given with a monoamine oxidase inhibitor or within a minimum of 14 days of discontinuing one, due to serotonin-syndrome risk. Critically, amitraz includes the amitraz-impregnated tick collar and amitraz dips, so screen the patient's parasiticide history, not just its medication list, before starting fluoxetine.

What are the most common side effects of fluoxetine in dogs? Sedation/lethargy (about 33% in label field studies) and decreased appetite (about 27%) are the leading signals, most pronounced early, along with vomiting, tremor, and diarrhea. Clinically meaningful weight loss (>=5%) occurred in nearly 30% of treated dogs, so weigh at every recheck. Seizures were reported even in dogs with no seizure history, and rare paradoxical aggression can occur.

Do you need to taper fluoxetine when stopping it? The Reconcile label states that because of the drug's long half-life it is not necessary to taper, and its slow elimination provides a built-in self-taper. In practice many clinicians still taper after prolonged use. Continue behavior modification after stopping to prevent relapse, and observe a 6-week washout before starting any drug that could interact with fluoxetine or norfluoxetine.

Can fluoxetine be used for aggression in dogs? The Reconcile label explicitly states it is not recommended for aggression, but generic fluoxetine is used off-label for owner-directed and other aggression at about 1.5 mg/kg/day paired with behavior therapy, with supporting peer-reviewed evidence over a 6-month course. Treat aggression cases as off-label, always combine with a behavior and safety plan, and set realistic owner expectations.